247133-44-4

Upstream product

• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1016258-66-4 1-(tert-butyl) 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate 
• 1016258-69-7 1-tert-butyl 4-ethyl 4-(aminomethyl)piperidine-1,4-dicarboxylate 
• 501-53-1 benzyl chloroformate 
• 4395-98-6 4-cyanopiperidine 

Downstream Products

• 247133-45-5 4-benzyloxycarbonylaminomethyl-1-(pyridin-4-yl)piperidine-4-carboxylic acid ethyl ester 
• 1207178-51-5 C₁₂H₂₁N₃O₂ 
• 1192189-66-4 4-[(benzyloxycarbonylamino)methyl]-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid 
• 1338251-61-8 C₂₀H₂₉N₃O₅ 
• 1338251-62-9 C₂₀H₂₇N₃O₄ 
• 1338251-65-2 C₁₆H₂₁N₃O₃*ClH 
• 1338251-66-3 C₁₄H₁₅Cl₂N₃O*ClH 
• 1338251-70-9 C₂₄H₂₉N₃O₄ 
• 1338251-71-0 C₂₄H₂₉N₃O₄ 
• 1338251-72-1 C₂₄H₂₉N₃O₄ 
• 1338251-73-2 C₂₄H₂₆F₃N₃O₃ 
• 1338251-74-3 C₂₄H₂₆F₃N₃O₃ 
• 1338251-75-4 C₂₄H₂₆F₃N₃O₃ 
• 1338251-76-5 C₂₈H₃₃N₃O₄ 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers

To obtain selective and potent inhibitor for T-type calcium channel by ligand based drug design, 4-piperidinecarboxylate and 4-piperidinecyanide derivatives were prepared and evaluated for in vitro and in vivo activity against α1G calcium channel. Among them, several compounds showed good T-type calcium channel inhibitory activity and minimal off-target activity over hERG channel (% inhibition at 10 μM = 61.85-71.99, hERG channel IC50 = 1.57 ± 0.14-4.98 ± 0.36 μM). Selected compound 31a was evaluated on SNL model of neuropathic pain and showed inhibitory effect on mechanical allodynia.

Amidine compounds

A compound of the formula [I] wherein R1, R2and R3are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the presen